Clene Nanomedicine Inc. announced the dosing of the first patient enrolled in the Phase 2 REPAIR-MS study with its lead nanocatalytic therapy, CNM-Au8, for the treatment of Multiple Sclerosis (MS). REPAIR-MS is Phase 2 single-center open label, sequential group, investigator blinded study examining the brain metabolic effects, safety, pharmacokinetics, and pharmacodynamics of CNM-Au8 in patients who have been diagnosed with MS within 15 years of screening. Participants drink about 2 oz. dose (60 mL) of the nanocrystal suspension daily each morning for 12 weeks. The objective of this study is to advance pharmacologic understanding of CNM-Au8 treatment effects on central nervous system biomarkers related to bioenergetics, neuronal metabolism, and oxidative stress, as indicators of target engagement for CNM-Au8 in patients with MS. The study is taking place at University of Texas Southwestern Medical Center and is being led by Benjamin Greenberg, MD, an internationally recognized expert in treating rare autoimmune disorders of the central nervous system.